Citations (54)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Huamei Wu, Xichen Tong, Lei Wang, Yan Huang & Luying Zhang. (2023) HPV vaccine information, knowledge, attitude, and recommendation intention among male college students in China. Human Vaccines & Immunotherapeutics 19:2.
Read now
Read now
Dylan A. Hendy, Alex Haven, Eric M. Bachelder & Kristy M. Ainslie. (2023) Preclinical developments in the delivery of protein antigens for vaccination. Expert Opinion on Drug Delivery 20:3, pages 367-384.
Read now
Read now
Hannah M. Priest & Adam P. Knowlden. (2015) Systematic review of primary prevention human papillomavirus interventions targeting college students. International Journal of Sexual Health 27:2, pages 125-144.
Read now
Read now
Ala-Eddin Al Moustafa, Rana Al-Awadhi, Nabiha Missaoui, Ishag Adam, Raika Durusoy, Lina Ghabreau, Nizar Akil, Hussain Gadelkarim Ahmed, Amber Yasmeen & Ghazi Alsbeih. (2014) Human papillomaviruses-related cancers. Human Vaccines & Immunotherapeutics 10:7, pages 1812-1821.
Read now
Read now
Anne Szarewski. (2012) Cervarix®: a bivalent vaccine against HPV types 16 and 18, with cross-protection against other high-risk HPV types. Expert Review of Vaccines 11:6, pages 645-657.
Read now
Read now
Articles from other publishers (49)
Fabian G. Martinez, Ryszard A. Zielke, Cyrielle E. Fougeroux, Lixin Li, Adam F. Sander & Aleksandra E. Sikora. (2023)
Development of a Tag/Catcher-mediated capsid virus-like particle vaccine presenting the conserved
Neisseria gonorrhoeae
SliC antigen that blocks human lysozyme
. Infection and Immunity.
Crossref
Crossref
Ling Han & Bingyi Zhang. (2023) Can prophylactic HPV vaccination reduce the recurrence of cervical lesions after surgery? Review and prospect. Infectious Agents and Cancer 18:1.
Crossref
Crossref
Francesca Ruzzi, Maria Sofia Semprini, Laura Scalambra, Arianna Palladini, Stefania Angelicola, Chiara Cappello, Olga Maria Pittino, Patrizia Nanni & Pier-Luigi Lollini. (2023) Virus-like Particle (VLP) Vaccines for Cancer Immunotherapy. International Journal of Molecular Sciences 24:16, pages 12963.
Crossref
Crossref
Qiaonan Hong, Jian Liu, Yuquan Wei & Xiawei Wei. (2023) Application of Baculovirus Expression Vector System (BEVS) in Vaccine Development. Vaccines 11:7, pages 1218.
Crossref
Crossref
Sumel Ashique, Afzal Hussain, Neda Fatima & Mohammad A. Altamimi. (2023) HPV pathogenesis, various types of vaccines, safety concern, prophylactic and therapeutic applications to control cervical cancer, and future perspective. VirusDisease 34:2, pages 172-190.
Crossref
Crossref
Annalaura Brai, Federica Poggialini, Claudia Pasqualini, Claudia Immacolata Trivisani, Chiara Vagaggini & Elena Dreassi. (2023) Progress towards Adjuvant Development: Focus on Antiviral Therapy. International Journal of Molecular Sciences 24:11, pages 9225.
Crossref
Crossref
Ayazhan Akhatova, Azliyati Azizan, Kuralay Atageldiyeva, Aiymkul Ashimkhanova, Aizada Marat, Yerbolat Iztleuov, Assem Suleimenova, Saikal Shamkeeva & Gulzhanat Aimagambetova. (2022) Prophylactic Human Papillomavirus Vaccination: From the Origin to the Current State. Vaccines 10:11, pages 1912.
Crossref
Crossref
Sebastian Wirsching, Marina Machtakova, Frauke Borgans, Leah Pretsch, Michael Fichter, Maximiliano L. Cacicedo, Héloïse Thérien-Aubin, Katharina Landfester & Stephan Gehring. (2022) OVA-PEG-R848 nanocapsules stimulate neonatal conventional and plasmacytoid dendritic cells. Frontiers in Pediatrics 10.
Crossref
Crossref
Arunima Sikdar, Rupali Gupta & Evzen Boura. (2022) Reviewing Antiviral Research against Viruses Causing Human Diseases -
a Structure-Guided Approach. Current Molecular Pharmacology 15:2, pages 306-337.
Crossref
Crossref
Jing-Xing Yang, Jen-Chih Tseng, Guann-Yi Yu, Yunping Luo, Chi-Ying F. Huang, Yi-Ren Hong & Tsung-Hsien Chuang. (2022) Recent Advances in the Development of Toll-like Receptor Agonist-Based Vaccine Adjuvants for Infectious Diseases. Pharmaceutics 14:2, pages 423.
Crossref
Crossref
Mariacristina Gagliardi & Marco Cecchini. 2022. Nanoparticle Therapeutics. Nanoparticle Therapeutics
499
528
.
Shannon M. Miller, Van Cybulski, Margaret Whitacre, Laura S. Bess, Mark T. Livesay, Lois Walsh, David Burkhart, Hélène G. Bazin & Jay T. Evans. (2020) Novel Lipidated Imidazoquinoline TLR7/8 Adjuvants Elicit Influenza-Specific Th1 Immune Responses and Protect Against Heterologous H3N2 Influenza Challenge in Mice. Frontiers in Immunology 11.
Crossref
Crossref
Renjie Wang, Wei Pan, Lei Jin, Weiming Huang, Yuehan Li, Di Wu, Chun Gao, Ding Ma & Shujie Liao. (2020) Human papillomavirus vaccine against cervical cancer: Opportunity and challenge. Cancer Letters 471, pages 88-102.
Crossref
Crossref
Xiangpeng Chen, Yong Zhang, Naiying Mao, Shuangli Zhu, Tianjiao Ji & Wenbo Xu. (2019) Intranasal immunization with coxsackievirus A16 virus-like particles confers protection against lethal infection in neonatal mice. Archives of Virology 164:12, pages 2975-2984.
Crossref
Crossref
Ahmad Ibrahim, Valerie Odon & Richard Kormelink. (2019) Plant Viruses in Plant Molecular Pharming: Toward the Use of Enveloped Viruses. Frontiers in Plant Science 10.
Crossref
Crossref
Theano Lagousi, Paraskevi Basdeki, John Routsias & Vana Spoulou. (2019) Novel Protein-Based Pneumococcal Vaccines: Assessing the Use of Distinct Protein Fragments Instead of Full-Length Proteins as Vaccine Antigens. Vaccines 7:1, pages 9.
Crossref
Crossref
Herney Andrés García-Perdomo, Julio Cesar Osorio, Adrian Fernandez, James Alejandro Zapata-Copete & Andrés Castillo. (2019) The effectiveness of vaccination to prevent the papillomavirus infection: a systematic review and meta-analysis. Epidemiology and Infection 147.
Crossref
Crossref
Marc Arbyn, Lan Xu, Cindy Simoens & Pierre PL Martin-Hirsch. (2018) Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database of Systematic Reviews 2020:3.
Crossref
Crossref
Geert Leroux-Roels, Jakob P Cramer, Paul M Mendelman, James Sherwood, Ralf Clemens, Annelies Aerssens, Ilse De Coster, Astrid Borkowski, Frank Baehner & Pierre Van Damme. (2018) Safety and Immunogenicity of Different Formulations of Norovirus Vaccine Candidate in Healthy Adults: A Randomized, Controlled, Double-Blind Clinical Trial. The Journal of Infectious Diseases 217:4, pages 597-607.
Crossref
Crossref
Oliver Damm, Johannes Horn, Rafael T. Mikolajczyk, Mirjam E. E. Kretzschmar, Andreas M. Kaufmann, Yvonne Deleré, Bernhard Ultsch, Ole Wichmann, Alexander Krämer & Wolfgang Greiner. (2017) Cost-effectiveness of human papillomavirus vaccination in Germany. Cost Effectiveness and Resource Allocation 15:1.
Crossref
Crossref
Ariel Esteban Bardach, Osvaldo Ulises Garay, María Calderón, Andrés Pichón-Riviére, Federico Augustovski, Sebastián García Martí, Paula Cortiñas, Marino Gonzalez, Laura T. Naranjo, Jorge Alberto Gomez & Joaquín Enzo Caporale. (2017) Health economic evaluation of Human Papillomavirus vaccines in women from Venezuela by a lifetime Markov cohort model. BMC Public Health 17:1.
Crossref
Crossref
Katharina B. Lauer, Ray Borrow & Thomas J. Blanchard. (2017) Multivalent and Multipathogen Viral Vector Vaccines. Clinical and Vaccine Immunology 24:1.
Crossref
Crossref
Nancy S. Handler, Marc Z. Handler, Slawomir Majewski & Robert A. Schwartz. (2015) Human papillomavirus vaccine trials and tribulations. Journal of the American Academy of Dermatology 73:5, pages 759-767.
Crossref
Crossref
Jorge Alberto Gomez, Alejandro Lepetic & Nadia Demarteau. (2014) Health economic analysis of human papillomavirus vaccines in women of Chile: perspective of the health care payer using a Markov model. BMC Public Health 14:1.
Crossref
Crossref
Yu-Li Lin, Yu-Chen Hu, Cheng-Chao Liang, Shih-Yeh Lin, Yu-Chih Liang, Hui-Ping Yuan & Bor-Luen Chiang. (2014) Enterovirus-71 Virus-Like Particles Induce the Activation and Maturation of Human Monocyte-Derived Dendritic Cells through TLR4 Signaling. PLoS ONE 9:10, pages e111496.
Crossref
Crossref
Marc Arbyn, Andrew Bryant, Pierre PL Martin-Hirsch, Lan Xu, Cindy Simoens & Lauri Markowitz. (2013) Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Sarah M McCusker, Ishbel Macqueen, Graham Lough, Alasdair I MacDonald, Christine Campbell & Sheila V Graham. (2013) Gaps in detailed knowledge of human papillomavirus (HPV) and the HPV vaccine among medical students in Scotland. BMC Public Health 13:1.
Crossref
Crossref
. (2013) Scientific Opinion on the maintenance of the list of QPS biological agents intentionally added to food and feed (2013 update). EFSA Journal 11:11.
Crossref
Crossref
J. Horn, O. Damm, M.E.E. Kretzschmar, Y. Deleré, O. Wichmann, A.M. Kaufmann, E. Garbe, A. Krämer, W. Greiner & R.T. Mikolajczyk. (2013) Estimating the long-term effects of HPV vaccination in Germany. Vaccine 31:19, pages 2372-2380.
Crossref
Crossref
Tania Rivera-Hernandez, Jon Hartas, Yang Wu, Yap P. Chuan, Linda H.L. Lua, Michael Good, Michael R. Batzloff & Anton P.J. Middelberg. (2013) Self-adjuvanting modular virus-like particles for mucosal vaccination against group A streptococcus (GAS). Vaccine 31:15, pages 1950-1955.
Crossref
Crossref
Zi-Zheng Zheng, Yuan-Yuan Sun, Min Zhao, Hui Huang, Jun Zhang, Ning-Shao Xia, Ji Miao & Qinjian Zhao. (2013) Specific interaction between hnRNP H and HPV16 L1 proteins: Implications for late gene auto-regulation enabling rapid viral capsid protein production. Biochemical and Biophysical Research Communications 430:3, pages 1047-1053.
Crossref
Crossref
. (2012) Scientific Opinion on the maintenance of the list of QPS biological agents intentionally added to food and feed (2012 update). EFSA Journal 10:12.
Crossref
Crossref
M. Poljak. (2012) Prophylactic human papillomavirus vaccination and primary prevention of cervical cancer: issues and challenges. Clinical Microbiology and Infection 18, pages 64-69.
Crossref
Crossref
George Creatsas & Efthimios Deligeoroglou. (2012) Microbial ecology of the lower genital tract in women with sexually transmitted diseases. Journal of Medical Microbiology 61:10, pages 1347-1351.
Crossref
Crossref
Nadia Demarteau, Chao-Hsiun Tang, Hui-Chi Chen, Chien-Jen Chen & Georges Van Kriekinge. (2012) Cost-Effectiveness Analysis of the Bivalent Compared with the Quadrivalent Human Papillomavirus Vaccines in Taiwan. Value in Health 15:5, pages 622-631.
Crossref
Crossref
Nadia Demarteau, Thomas Breuer & Baudouin Standaert. (2012) Selecting a Mix of Prevention Strategies against Cervical Cancer for Maximum Efficiency with an Optimization Program. PharmacoEconomics 30:4, pages 337-353.
Crossref
Crossref
Oren Shavit, Raanan Raz, Michal Stein, Gabriel Chodick, Eduardo Schejter, Yehuda Ben-David, Raanan Cohen, Daphna Arbel & Varda Shalev. (2012) Evaluating the Epidemiology and Morbidity Burden Associated with Human Papillomavirus in Israel. Applied Health Economics and Health Policy 10:2, pages 87-97.
Crossref
Crossref
Yu-Li Lin, Chun-I Yu, Yu-Chen Hu, Tze-Jiun Tsai, Yin-Chieh Kuo, Wei-Kuang Chi, Ae-Ning Lin & Bor-Luen Chiang. (2012) Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles. Vaccine 30:7, pages 1305-1312.
Crossref
Crossref
Abdelkader El Hasnaoui, Nadia Demarteau, Denis Granados, Baudouin Standaert & Bruno Detournay. (2011) Public health impact of human papillomavirus vaccination on prevention of cervical cancer in France. International Journal of Public Health 57:1, pages 149-158.
Crossref
Crossref
Franco Borruto & Ciro Comparetto. 2012. HPV and Cervical Cancer. HPV and Cervical Cancer
273
326
.
Austin Pantel, Cheolho Cheong, Durga Dandamudi, Elina Shrestha, Saurabh Mehandru, Luke Brane, Darren Ruane, Angela Teixeira, Leonia Bozzacco, Ralph M. Steinman & M. Paula Longhi. (2011) A new synthetic TLR4 agonist, GLA, allows dendritic cells targeted with antigen to elicit Th1 T‐cell immunity in vivo. European Journal of Immunology 42:1, pages 101-109.
Crossref
Crossref
. (2011) Scientific Opinion on the maintenance of the list of QPS biological agents intentionally added to food and feed (2011 update). EFSA Journal 9:12, pages 2497.
Crossref
Crossref
Soumyabrata Roy, Shyamal Goswami, Anamika Bose, Kuntal Kanti Goswami, Koustav Sarkar, Krishnendu Chakraborty, Tathagata Chakraborty, Smarajit Pal, Atanu Haldar, Parthasarathi Basu, Jaydip Biswas & Rathindranath Baral. (2011) Defective dendritic cell generation from monocytes is a potential reason for poor therapeutic efficacy of interferon α2b (IFNα2b) in cervical cancer. Translational Research 158:4, pages 200-213.
Crossref
Crossref
S. Capri, R. Gasparini, D. Panatto & N. Demarteau. (2011) Cost–consequences evaluation between bivalent and quadrivalent HPV vaccines in Italy: The potential impact of different cross-protection profiles. Gynecologic Oncology 121:3, pages 514-521.
Crossref
Crossref
Marc Arbyn, Andrew Bryant, Philippe Beutels, Pierre PL Martin-Hirsch, Evangelos Paraskevaidis, Elke Van Hoof, Marc Steben, Youlin Qiao, Fang-Hui Zhao, Achim Schneider, Andreas Kaufmann, Joakim Dillner, Lauri Markowitz & Allan Hildesheim. 1996. Cochrane Database of Systematic Reviews. Cochrane Database of Systematic Reviews.
Nadia Demarteau, Bruno Detournay, Bertrand Tehard, Abdelkader El Hasnaoui & Baudouin Standaert. (2010) A generally applicable cost-effectiveness model for the evaluation of vaccines against cervical cancer. International Journal of Public Health 56:2, pages 153-162.
Crossref
Crossref
John J. Kerrigan, Qing Xie, Robert S. Ames & Quinn Lu. (2011) Production of protein complexes via co-expression. Protein Expression and Purification 75:1, pages 1-14.
Crossref
Crossref
. (2010) Scientific Opinion on the maintenance of the list of QPS biological agents intentionally added to food and feed (2010 update). EFSA Journal 8:12.
Crossref
Crossref
Giuseppina D'Andrilli, Alessandro Bovicelli & Antonio Giordano. (2010) HPV vaccines: State of the art. Journal of Cellular Physiology 224:3, pages 601-604.
Crossref
Crossref